Axogen (Axogen) Long-Term Capital Lease Obligation : $21.1 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Axogen Long-Term Capital Lease Obligation?

Axogen's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $21.1 Mil.

Axogen's quarterly Long-Term Capital Lease Obligation declined from Jun. 2023 ($20.1 Mil) to Sep. 2023 ($19.9 Mil) but then increased from Sep. 2023 ($19.9 Mil) to Dec. 2023 ($21.1 Mil).

Axogen's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($20.8 Mil) to Dec. 2022 ($20.4 Mil) but then increased from Dec. 2022 ($20.4 Mil) to Dec. 2023 ($21.1 Mil).

Axogen Long-Term Capital Lease Obligation Historical Data

The historical data trend for Axogen's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Long-Term Capital Lease Obligation Chart

Axogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.60

20.87

20.80

20.41

21.14

Axogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															20.41	20.09	20.13	19.93	21.14

Axogen (NAS:AXGN) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Axogen Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Axogen's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Axogen (Axogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

LT3:Germany

Address

13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615

Website

https://www.axogeninc.com

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Executives

Peter J Mariani	officer: Chief Financial Officer	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr.	director	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Marc A Began	officer: EVP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall	director	13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Karen L. Zaderej	director, officer: CEO	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Michael Patrick Donovan	officer: VP Operations	C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Maria D. Martinez	officer: Chief Human Resources Officer	C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Alan M Levine	director	C/O AXOGEN, INC., 13631 PROGRESS BLVD. - SUITE 400, ALACHUA FL 32615
Mark Stephen Gold	director	13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Quentin S. Blackford	director	7475 LUSK BLVD., SAN DIEGO CA 92121